News

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.
GEN - Genetic Engineering and Biotechnology News4d
Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery
While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.
Former Google CEO warns ‘AI could surpass human intelligence in next few years’; what is artificial superintelligence and why it matters
Former Google CEO Eric Schmidt warns that Artificial Superintelligence (ASI), surpassing human intelligence, is imminent. He ...
What is Artificial Super-intelligence? Former Google CEO Eric Schmidt warns AI will soon outsmart humanity and we are not ready
Former Google CEO Eric Schmidt warns that Artificial Super-intelligence (ASI) could surpass collective human intelligence within six years. Speaking on the Special Competitive Studies Project podcast, ...